Literature DB >> 20207878

Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma.

Jeremy D Keenan1, Takele Lakew, Wondu Alemayehu, Muluken Melese, Travis C Porco, Elizabeth Yi, Jenafir I House, Zhaoxia Zhou, Kathryn J Ray, Nisha R Acharya, John P Whitcher, Bruce D Gaynor, Thomas M Lietman.   

Abstract

It is unclear how the prevalence of clinically active trachoma correlates with the prevalence of ocular chlamydial infection at the community level. In 24 villages from a cluster-randomized clinical trial of mass azithromycin distributions in Ethiopia, the correlation between the prevalence of clinical activity (on examination) and chlamydial infection (by polymerase chain reaction) was moderately strong before mass antibiotic treatments (Pearson's correlation coefficient r = 0.75, 95% confidence interval [CI] = 0.52-0.87), but decreased at each time point during four biannual treatments (at 24 months, r = 0.15, 95% CI = -0.14-0.41). One year after the final treatment, the correlation coefficient had increased, but not to the pre-treatment level (r = 0.55, 95% CI = 0.30-0.73). In a region with hyperendemic trachoma, conjunctival examination was a useful indicator of the prevalence of chlamydial infection before treatments, less useful during mass treatments, but regained utility by one year after treatments had stopped.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20207878      PMCID: PMC2829914          DOI: 10.4269/ajtmh.2010.09-0315

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  26 in total

1.  Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal.

Authors:  S O Holm; H C Jha; R C Bhatta; J S Chaudhary; B B Thapa; D Davis; R P Pokhrel; M Yinghui; M Zegans; J Schachter; K D Frick; L Tapert; T M Lietman
Journal:  Bull World Health Organ       Date:  2003-07-07       Impact factor: 9.408

2.  The natural history of endemic trachoma: a longitudinal study.

Authors:  H R Taylor; J A Siler; H A Mkocha; B Munoz; S West
Journal:  Am J Trop Med Hyg       Date:  1992-05       Impact factor: 2.345

3.  Pooling of Chlamydia laboratory tests to determine the prevalence of ocular Chlamydia trachomatis infection.

Authors:  J Diamant; R Benis; J Schachter; J Moncada; F Pang; H C Jha; R C Bhatta; T Porco; T Lietman
Journal:  Ophthalmic Epidemiol       Date:  2001-07       Impact factor: 1.648

4.  A simple system for the assessment of trachoma and its complications.

Authors:  B Thylefors; C R Dawson; B R Jones; S K West; H R Taylor
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

5.  Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas?

Authors:  Mariko Bird; Chandler R Dawson; Julius S Schachter; Yinghui Miao; Ahmed Shama; Ahmed Osman; Ahmad Bassem; Thomas M Lietman
Journal:  J Infect Dis       Date:  2003-04-30       Impact factor: 5.226

6.  How reliable is the clinical exam in detecting ocular chlamydial infection?

Authors:  Kevin Miller; Greg Schmidt; Muluken Melese; Wondu Alemayehu; Elizabeth Yi; Vicky Cevallos; Cathy Donnellan; Lynn Olinger; Demeke Fantaye; Bruce Gaynor; John P Whitcher; Thomas Lietman
Journal:  Ophthalmic Epidemiol       Date:  2004-07       Impact factor: 1.648

7.  Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments.

Authors:  Muluken Melese; Jaya Devi Chidambaram; Wondu Alemayehu; David Chung Lee; Elizabeth H Yi; Vicky Cevallos; Zhaoxia Zhou; Cathy Donnellan; Michael Saidel; John P Whitcher; Bruce D Gaynor; Thomas M Lietman
Journal:  JAMA       Date:  2004-08-11       Impact factor: 56.272

8.  Does clinical diagnosis indicate ocular chlamydial infection in areas with a low prevalence of trachoma?

Authors:  Jocelyn Thein; Puning Zhao; Hansheng Liu; Jingjing Xu; Hem Jha; Yinghui Miao; Louis Pizzarello; Lisa Tapert; Julius Schachter; Michèle Mabon; Susan Osaki-Holm; Thomas Lietman; Anne Paxton
Journal:  Ophthalmic Epidemiol       Date:  2002-10       Impact factor: 1.648

9.  Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages.

Authors:  Matthew J Burton; Martin J Holland; Nkoyo Faal; Esther A N Aryee; Neal D E Alexander; Momodou Bah; Hannah Faal; Sheila K West; Allen Foster; Gordon J Johnson; David C W Mabey; Robin L Bailey
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-10       Impact factor: 4.799

10.  Reduction and return of infectious trachoma in severely affected communities in Ethiopia.

Authors:  Takele Lakew; Jenafir House; Kevin C Hong; Elizabeth Yi; Wondu Alemayehu; Muluken Melese; Zhaoxia Zhou; Kathryn Ray; Stephanie Chin; Emmanuel Romero; Jeremy Keenan; John P Whitcher; Bruce D Gaynor; Thomas M Lietman
Journal:  PLoS Negl Trop Dis       Date:  2009-02-03
View more
  29 in total

1.  Slow resolution of clinically active trachoma following successful mass antibiotic treatments.

Authors:  Jeremy D Keenan; Takele Lakew; Wondu Alemayehu; Muluken Melese; Jenafir I House; Nisha R Acharya; Travis C Porco; Bruce D Gaynor; Thomas M Lietman
Journal:  Arch Ophthalmol       Date:  2011-04

2.  Active trachoma is associated with increased conjunctival expression of IL17A and profibrotic cytokines.

Authors:  Matthew J Burton; Athumani Ramadhani; Helen A Weiss; Victor Hu; Patrick Massae; Sarah E Burr; Wahida Shangali; Martin J Holland; David C W Mabey; Robin L Bailey
Journal:  Infect Immun       Date:  2011-09-12       Impact factor: 3.441

3.  What is causing active trachoma? The role of nonchlamydial bacterial pathogens in a low prevalence setting.

Authors:  Matthew J Burton; Victor H Hu; Patrick Massae; Sarah E Burr; Caroline Chevallier; Isaac A Afwamba; Paul Courtright; Helen A Weiss; David C W Mabey; Robin L Bailey
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

4.  Can clinical signs of trachoma be used after multiple rounds of mass antibiotic treatment to indicate infection?

Authors:  Beatriz Munoz; Dianne Stare; Harran Mkocha; Charlotte Gaydos; Thomas Quinn; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-11       Impact factor: 4.799

5.  Using a nonparametric multilevel latent Markov model to evaluate diagnostics for trachoma.

Authors:  Artemis Koukounari; Irini Moustaki; Nicholas C Grassly; Isobel M Blake; María-Gloria Basáñez; Manoj Gambhir; David C W Mabey; Robin L Bailey; Matthew J Burton; Anthony W Solomon; Christl A Donnelly
Journal:  Am J Epidemiol       Date:  2013-04-01       Impact factor: 4.897

6.  Serology for trachoma surveillance after cessation of mass drug administration.

Authors:  Diana L Martin; Rhiannon Bid; Frank Sandi; E Brook Goodhew; Patrick A Massae; Augustin Lasway; Heiko Philippin; William Makupa; Sandra Molina; Martin J Holland; David C W Mabey; Chris Drakeley; Patrick J Lammie; Anthony W Solomon
Journal:  PLoS Negl Trop Dis       Date:  2015-02-25

7.  Pathogenesis of progressive scarring trachoma in Ethiopia and Tanzania and its implications for disease control: two cohort studies.

Authors:  Matthew J Burton; Saul N Rajak; Victor H Hu; Athumani Ramadhani; Esmael Habtamu; Patrick Massae; Zerihun Tadesse; Kelly Callahan; Paul M Emerson; Peng T Khaw; David Jeffries; David C W Mabey; Robin L Bailey; Helen A Weiss; Martin J Holland
Journal:  PLoS Negl Trop Dis       Date:  2015-05-13

Review 8.  Stopping azithromycin mass drug administration for trachoma: A systematic review.

Authors:  Hamidah Mahmud; Emma Landskroner; Abdou Amza; Solomon Aragie; William W Godwin; Anna de Hostos Barth; Kieran S O'Brien; Thomas M Lietman; Catherine E Oldenburg
Journal:  PLoS Negl Trop Dis       Date:  2021-07-08

9.  The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children.

Authors:  Jennifer S Lee; Beatriz E Muñoz; Harran Mkocha; Charlotte A Gaydos; Thomas C Quinn; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2014-04-10

10.  Plasmid copy number and disease severity in naturally occurring ocular Chlamydia trachomatis infection.

Authors:  Anna R Last; Chrissy h Roberts; Eunice Cassama; Meno Nabicassa; Sandra Molina-Gonzalez; Sarah E Burr; David C W Mabey; Robin L Bailey; Martin J Holland
Journal:  J Clin Microbiol       Date:  2013-11-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.